Ezose Sciences Enters Glycomics Research Agreement with Kyowa Hakko Kirin

  Ezose Sciences Enters Glycomics Research Agreement with Kyowa Hakko Kirin

 Kyowa Hakko Kirin to Fund Projects Exploiting Ezose’s GlycanMap®technology

Business Wire

PINE BROOK, N.J. -- January 28, 2013

Ezose Sciences Inc. today announced that it has entered a research agreement
with Kyowa Hakko Kirin Co. Ltd. to collaborate on glycomics studies using
Ezose’s proprietary GlycanMap®technology platform.

Under terms of the research agreement, Kyowa Hakko Kirin will fund several
glycan-biomarker and other discovery projects, with an option for further
research and development. Other details of the agreement were not disclosed.

“We look forward to putting our unique glycan-analysis capabilities to the
service of the specific research interests of Kyowa Hakko Kirin,” said
Hidehisa Asada, Ph.D., Vice President, Research & Development of Ezose. “As
the structure of our collaboration anticipates, the research will seek new
discoveries that enable novel therapeutic strategies and sustain the flow of
new products to market.”

About Glycomics

Glycomics is the study of glycans, the sugar chains that during the
biochemical process known as glycosylation become attached to many proteins
expressed by human cells. The particular glycans involved may crucially
determine the function of the resulting glycoprotein and its role in health
and disease.

Glycomics is a natural complement to genomics and proteomics, but it has
traditionally been hindered by the lack of practical high-throughput and
quantitative technologies. Ezose’s proprietary GlycanMap® platform addresses
this need by combining, in an automated 96-well format, high-throughput glycan
enrichment with specialized MALDI-TOF mass spectrometry and custom
bioinformatics to both structurally identify and quantitate glycans present in
complex biological samples. Such glycans can serve as novel biomarkers to aid
in the development of drugs, vaccines, and diagnostic tests, including
companion diagnostics. In addition, glycomics holds potential for uncovering
new therapeutic targets and mechanisms and for guiding the development and
manufacture of glycosylated biologics and biosimilars.

About Ezose

Ezose (pronounced ā-zōse) Sciences Inc., based in Pine Brook, NJ, is dedicated
to advancing glycomics to improve scientific understanding and healthcare.
Ezose’s proprietary GlycanMap® technology platform brings a new dimension to
biomarker discovery by enabling glycomics research on a scale comparable to
that of genomics and proteomics. Ezose offers glycomics capabilities ranging
from glycan analytics and biomarker discovery to diagnostic development and
commercialization. The company tailors these capabilities to the needs of
corporate partners under collaborative R&D and analytical-services agreements.

Established in 2009 as a US company, Ezose is an affiliate of the Diagnostics
Division of Shionogi & Co., Ltd., Osaka, Japan. For more information, visit
www.ezose.com.

About Kyowa Hakko Kirin

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on
its core business area of oncology, nephrology and immunology/allergy. Kyowa
Hakko Kirin leverages antibody-related leading-edge technologies to discover
and develop innovative new drugs aiming to become a global specialty
pharmaceutical company which contributes to the health and well-being of
people around the world. For more information, visit
http://www.kyowa-kirin.com.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are
based on expectations in light of the information currently available,
assumptions that are subject to risks and uncertainties which could cause
actual results to differ materially from these statements. Risks and
uncertainties include general domestic and international economic conditions
such as general industry and market conditions, and changes of interest rate
and currency exchange rate. These risks and uncertainties particularly apply
with respect to product-related forward-looking statements. Product risks and
uncertainties include, but are not limited to, completion and discontinuation
of clinical trials; obtaining regulatory approvals; claims and concerns about
product safety and efficacy; technological advances; adverse outcome of
important litigation; domestic and foreign healthcare reforms and changes of
laws and regulations. Also for existing products, there are manufacturing and
marketing risks, which include, but are not limited to, inability to build
production capacity to meet demand, unavailability of raw materials and entry
of competitive products. The company disclaims any intention or obligation to
update or revise any forward looking statements whether as a result of new
information, future events or otherwise.

Contact:

Ezose business:
Scott A. Siegel, Ph.D., Chief Operating Officer
Main: 862-926-1950
Direct: 862-926-1952
info@ezose.com
or
Ezose media:
Richard Koenig at Biosyntax LLC
Office: 610-359-1626
Cell: 610-213-0725
rick@biosyntaxllc.com